Newsroom

Pangaea investigators, co-authors of results presented at ASCO 2016


Targeting RET in patients with RET-rearranged lung cancers: results from a global registry.
Oliver Gautschi, Juergen Wolf, Julien Mazieres, Julie Milia, Thomas Filleron, David Paul Carbone, Mark M. Awad, D. Ross Camidge, Benjamin Besse, Byoung Chul Cho, Pasi A. Janne, Florian Cabillic, Jin-Yuan Shih, Michel Van Den Heuvel, Nir Peled, Daniel D. Karp, Rafael Rosell, Mark G. Kris, Alexander E. Drilon, on behalf of the GLORY investigators.
Poster #164061

Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non–small cell lung cancer (NSCLC): phase (ph) 1/2 trial results.
Corey J. Langer, Scott N. Gettinger, Lyudmila Bazhenova, Ravi Salgia, Kathryn A. Gold, Rafael Rosell, Alice Tsang Shaw, Glen J. Weiss, David J. Dorer, Victor M. Rivera, Frank G. Haluska, David Kerstein, D. Ross Camidge.
Poster #164989

Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status.
Author(s): Scott N. Gettinger, Sen Zhang, J. Graeme Hodgson, Lyudmila Bazhenova, Sjaak Burgers, Dong-Wan Kim, Daniel Shao-Weng Tan, Han A. Koh, James C. M. Ho, Santiago Viteri Ramirez, Alice Tsang Shaw, Glen J. Weiss, Corey J. Langer, Rudolf M. Huber, Myung-Ju Ahn, William G Reichmann, David Kerstein, Victor M. Rivera, D. Ross Camidge.
Poster #9060

Multi-arm, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy in malignant pleural mesothelioma (MPM)
Jose Manuel Trigo Perez, Emilie Van Brummelen, Evgeny Levchenko, Manuel Domine, Pilar Garrido Lopez, Hedy L. Kindler, Daniel Morgensztern, Marjorie Glass Zauderer, Johan F. Vansteenkiste, Santiago Viteri Ramirez, Katherine Baker Neblett, Jeffrey Botbyl, Eddie Jose, Adina Zajac, Ionel Mitrica, Robert S. Sikorski, Li Yan
Poster #8557

Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study
Jong-Seok Lee, Ji-Youn Han, Myung-Ju Ahn, In-Jae Oh, HyeRyun Kim, Dae Ho Lee, Erin Marie Bertino, Santiago Viteri Ramirez, Nathan A. Pennell, Antoinette J. Wozniak, Joan H. Schiller, Chester Lin, Harold N. Keer, Mohammad Azab, Benjamin Besse, D. Ross Camidge
Poster #9059

Selective CHK1 inhibition as a therapeutic approach in NSCLC, a new option for KRAS mutated patients and squamous cell carcinoma.
Daniela Morales-Espinosa, Silvia García-Román, Miguel Angel Molina-Vila, Ana Gimenez Capitan, Jordi Bertran-Alamillo, Pedro Mendez, Santiago Viteri Ramirez, Niki Karachaliou, Rafael Rosell.
Poster #169740

EGFR  mutant cfDNA and CTC detection as biomarkers in patients diagnosed with advanced non-small cell lung cancer.
Silvia Calabuig-Fariñas, Eloisa Jantus-Lewintre, Clara Mayo-de las Casas, Nuria Jordana-Ariza, Ariadna Balada, Ana Blasco, Miguel Angel Molina-Vila, Rafael Rosell, Carlos Camps.
Proceedings #169534

 




We use first and third party cookies to track your browsing habits on our website in order to provide you with better quality and security, and improve the services offered through this website. If users do not explicitly confirm that they consent to the installation of cookies but continue to browse our website, we will assume that they have agreed and we will inform them accordingly about the possibility of blocking or deleting any previously installed cookies by adjusting their browser settings. You can find out more about cookies in our "Cookie Policy".

COOKIE POLICY